Fintel reports that on January 20, 2026, Chardan Capital initiated coverage of ZOOZ Strategy (NasdaqCM:ZOOZ) with a Buy recommendation. Analyst Price Forecast Suggests 96.74% Downside As of November 9 ...
Chardan initiated coverage of Mind Medicine (MNMD) with a Buy rating and $20 price target The firm cites the potential of the company’s lead asset MM120 for the treatment of generalized anxiety ...
TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while reducing its price target from $82 to $74. The firm stated that the ...
NEW YORK, June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series ...
Chardan Research weighed in on VinFast Auto (VFS) after the Vietnamese electric vehicle maker issued its 2025 deliveries ...
Chardan downgraded Cargo Therapeutics (CRGX) to Neutral from Buy without a price target The company will be discontinuing the Phase II FIRCE-1 clinical trial of its lead autologous CD22 CAR-T ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces ...
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases ...
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today ...
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the 12 Best Genomics Stocks to Invest In. TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback